---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-021548"
form_type: "8-K"
ticker: "RGNX"
cik: "0001590877"
company_name: "REGENXBIO Inc."
filed_at: "2022-11-03T23:59:59+00:00"
generated_at: "2026-06-22T09:03:31.645112+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# REGENXBIO Q3 net loss $75.5M; cash $617M; RGX-314 BLA on track for 2024

## Summary
- Net loss of $75.5M ($1.75/share) vs $58.4M ($1.37/share) in Q3 2021; revenue $26.5M, down from $30.8M.
- Cash, equivalents & marketable securities $617M as of Sept 30, 2022, down from $849.3M at Dec 31, 2021; runway into 2025.
- RGX-314 subretinal pivotal trials (ATMOSPHERE, ASCENT) enrolling; BLA filing planned in 2024. AAVIATE and ALTITUDE trials expanded with new cohorts.
- RGX-202 AFFINITY DUCHENNE Phase I/II trial on track for first patient dosing in H1 2023; RGX-121 CAMPSIITE pivotal trial enrolling for MPS II.
- Zolgensma royalty revenue $25.2M in Q3 2022 vs $30.3M in Q3 2021; Novartis reported Q3 global sales of $319M.

## SEC filing metadata
- accession: 0000950170-22-021548
- form_type: 8-K
- ticker: RGNX
- cik: 0001590877
- company_name: REGENXBIO Inc.
- filed_at: 2022-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590877/000095017022021548/0000950170-22-021548-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590877/000095017022021548/rgnx-20221103.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-021548
- JSON: https://secwatch.observer/filing/0000950170-22-021548.json
- Plain text: https://secwatch.observer/filing/0000950170-22-021548.txt

## Key facts
- Earnings Releases
  REGENXBIO Inc. reported financial results for third quarter ended September 30, 2022.
  - Period: third quarter ended September 30, 2022
  - Result: reported results
  source text: On November 3, 2022, REGENXBIO Inc. (the “Company”) issued a press release regarding its results of operations and financial condition for the quarter ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1590877/000095017022021548/0000950170-22-021548-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.